

Systematic Review



Effect of Postoperative Coffee Consumption on Postoperative Ileus after Abdominal Surgery: An Updated Systematic Review and Meta-Analysis

Jun Watanabe ^{1,2,*}, Atsushi Miki ¹, Masaru Koizumi ¹, Kazuhiko Kotani ², and Naohiro Sata ¹

- ¹ Department of Surgery, Division of Gastroenterological, General and Transplant Surgery, Jichi Medical University, Shimotsuke-City 329-0498, Japan; amiki@jichi.ac.jp (A.M.); mkoizumi@jichi.ac.jp (M.K.); sata2018@jichi.ac.jp (N.S.)
- ² Division of Community and Family Medicine, Jichi Medical University, Shimotsuke-City 329-0498, Japan; kazukotani@jichi.ac.jp
- * Correspondence: m06105jw@jichi.ac.jp; Tel.: +81-285-58-7371; Fax: +81-285-44-3234

Abstract: Background: Previous systematic reviews have not clarified the effect of postoperative coffee consumption on the incidence of postoperative ileus (POI) and the length of hospital stay (LOS). We aimed to assess its effect on these postoperative outcomes. Methods: Studies evaluating postoperative coffee consumption were searched using electronic databases until September 2021 to perform random-effect meta-analysis. The quality of evidence was assessed using the Cochrane risk-of-bias tool. Caffeinated and decaffeinated coffee were also compared. Results: Thirteen trials (1246 patients) and nine ongoing trials were included. Of the 13 trials, 6 were on colorectal surgery, 5 on caesarean section, and 2 on gynecological surgery. Coffee reduced the time to first defecation (mean difference (MD) -10.1 min; 95% confidence interval (CI) = -14.5 to -5.6), POI (risk ratio 0.42; 95% CI = 0.26 to 0.69); and LOS (MD -1.5; 95% CI = -2.7 to -0.3). This trend was similar in colorectal and gynecological surgeries. Coffee had no adverse effects. There was no difference in POI or LOS between caffeinated and decaffeinated coffee (p > 0.05). The certainty of evidence was low to moderate. Conclusion: This review showed that postoperative coffee consumption, regardless of caffeine content, likely reduces POI and LOS after colorectal and gynecological surgery.

Keywords: abdominal surgery; caffeine; coffee; ileus; length of stay; meta-analysis; systematic review

1. Introduction

Postoperative ileus (POI), defined as the transient cessation of coordinated bowel motility, is a common cause of delayed return to normal bowel function after abdominal surgery (e.g., colorectal and gynecologic surgery), occurring in 10–15% of cases [1,2]. Delayed defecation associated with POI causes vomiting, bloating, and intolerance to food, and POI often leads to invasive interventions, such as nasogastric tube insertion [3]. POI increases postoperative length of hospital stay (LOS) and treatment-related costs [4,5]. POI and LOS are important postoperative outcomes because prolonged LOS and increased risk of morbidity due to POI have been shown to reduce patients' quality of life and increase hospital expenditures [4–6].

Coffee is the most widely consumed pharmacological substance worldwide [7]. Caffeine exerts anti-inflammatory effects on the gastrointestinal and cardiovascular systems, mediated by its antagonistic effects on A2A receptors on immune cells, such as T and B cells and macrophages [8,9]. Since the implementation of enhanced recovery protocols (ERPs), multimodal strategies have been used to improve the postoperative return of gastrointestinal function [10,11]. Recommendations regarding the use of postoperative coffee vary in various international ERPs [10,11]. Previous systematic reviews did not demonstrate that LOS and POI were statistically significantly reduced, because of the small



Citation: Watanabe, J.; Miki, A.; Koizumi, M.; Kotani, K.; Sata, N. Effect of Postoperative Coffee Consumption on Postoperative Ileus after Abdominal Surgery: An Updated Systematic Review and Meta-Analysis. *Nutrients* **2021**, *13*, 4394. https://doi.org/10.3390/ nu13124394

Academic Editor: Patrick Lauwers

Received: 16 October 2021 Accepted: 7 December 2021 Published: 8 December 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). number of trials [12–15]. In addition, it is unclear whether coffee or decaffeinated coffee is effective in treating POI [12].

Coffee, a popular and easily available beverage worldwide, could also be clinically significant if shown to prevent POI incidence in addition to shortening LOS. In terms of ERPs, colorectal and gynecological surgeries are treated similarly because of the manipulation of the bowel [10,11]. Therefore, the present updated systematic review and meta-analysis aimed to assess the effect of postoperative coffee consumption on POI after abdominal surgery, including colorectal surgery, cesarean section, and gynecological surgery.

2. Material and Methods

2.1. Protocol

We followed the Preferred Reporting Items for Systematic Review and Meta-Analysis 2020 (PRISMA 2020) (Appendix A) [16]. This protocol was registered on protocols.io (https://doi.org/10.17504/protocols.io.bymmpu46).

2.2. Inclusion Criteria

Randomized controlled trials (RCTs) that assessed the effect of postoperative coffee consumption after abdominal surgery were included. No language, country, observation period, or publication year restrictions were applied. Review articles, case series, and case reports were excluded. The intervention of interest was postoperative 100–150 mL coffee consumption, three times per day, for 10–20 min. The control group consumed water, tea, or a placebo. The primary outcomes were time to first defecation (hours), LOS (days), and POI. The secondary outcomes were the time to first flatus (hours), the time to first bowel movement (hours), the time to tolerance of solid food (hours), and adverse events.

2.3. Search Method

The following electronic databases and trial registries were searched: MEDLINE (PubMed), Cochrane Central Register of Controlled Trials (Cochrane Library), EMBASE (Dialog) (Appendix B), the World Health Organization International Clinical Trials Platform Search Portal (ICTRP), and ClinicalTrials.gov (Appendix C). The reference lists were checked for studies, including international guidelines [10,11], as well as reference lists of eligible studies and articles citing eligible studies. The authors of the original studies were asked for unpublished or additional data if necessary.

2.4. Data Collection and Analysis

Two independent reviewers (J.W. and A.M.) performed screening, data extraction, and assessment of the risk of bias using the Risk of Bias 2 tool [17] and assessed the quality of evidence based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach [18]. Disagreements between the two reviewers were discussed, and if necessary, a third reviewer (K.K.) was consulted.

The relative risk ratios (RRs) and the 95% confidence intervals (CIs) were calculated for the binary variables, POI, and adverse events. The mean differences (MDs) and 95% CIs were calculated for the continuous variables, LOS (days), the time to first defecation (hours), the time to first flatus (hours), the time to first bowel movement (hours), and time to tolerance of solid food (hours). Intention-to-treat analysis was performed for dichotomous data as far as possible. For continuous data, missing data were not imputed based on the recommendations of the Cochrane handbook [19]. In cases where missing data were not known after contacting the original authors, the standard deviation was calculated using the method provided in the Cochrane handbook [19] or a previously validated method [20]. A random-effects meta-analysis was performed using Review Manager software (RevMan 5.4.2).

2.5. Assessment of Heterogeneity and Reporting Bias

Statistical heterogeneity was evaluated by visual inspection of the forest plots and calculating the I^2 statistic ($I^2 = 0-40\%$, might not be important; 30–60\%, moderate hetero-

geneity; 50–90%, substantial heterogeneity; and 75–100%, considerable heterogeneity) [19]. When there was substantial heterogeneity ($I^2 > 50\%$), we assessed the reason for the heterogeneity. Cochrane's chi² test (Q-test) was performed on the I^2 statistic, and a *p*-value less than 0.10 was defined as statistically significant. We searched the clinical trial registry system (ClinicalTrials.gov and ICTRP) to assess any reporting bias. Potential publication bias was evaluated through visual inspection of the funnel plots.

2.6. Additional Analysis

The following subgroup analyses were performed: surgery types (colorectal resection, cesarean section, or gynecological resection) and coffee types (caffeinated or decaffeinated coffee). The following sensitivity analysis was performed: exclusion of studies using imputed statistics.

3. Results

Figure 1 shows the study search process. After the removal of duplicates, 1005 records were screened, of which 31 underwent full-text review and 1 article was added after reviewing reference lists. Finally, 27 studies were included in the qualitative synthesis. The 27 studies comprised 9 ongoing trials (NCT 02510911, NCT02639728, NCT03143621, NCT03191877, NCT03712891, NCT04205058, NCT04547868, IRCT20200116046153N1, and CTRI/2021/04/033141), 5 protocols without results (NCT00130026, NCT01130675, NCT02250924, NCT03660267, and NCT03815877), and 13 clinical trials (1246 patients) [21–33].



Figure 1. Flow of the study search process.

Table 1 shows the characteristics of the included clinical trials. Of the 13 trials [21–33], 6 were on colorectal surgery, 5 on cesarean section, and 2 on gynecological surgery. The intervention was caffeinated coffee in 10 trials and decaffeinated coffee in 3 trials.

Authors [Ref. No.]	Year	Country	No.	Age, Year	Male, %	Surgical	Coffee	Volume, mL	Frequency	Control
Müller [21]	2012	Germany	79	61	56	CRS	Caffeine	100	TDS	Water
Dulskas [22]	2015	Lithuania	90	65	53	CRS	Caffeine, Decaf	100	TDS	Water
Piric [23]	2015	Bosnia and Herzegovina	58	63	59	CRS	Caffeine	100	TDS	Tea
Göymen [24]	2016	Turkey	75	50	0	CS	Decaf	100	TDS	Water, no intervention
Güngördük [25]	2017	Turkey	114	55	0	GS	Caffeine	100	TDS	No intervention
Mohamed [26]	2018	Egypt	210	NR	0	CS	NR	NR	NR	No intervention
Rabiepoor [27]	2018	Iran	100	28	0	CS	Caffeine	100	TDS	Water
Hasler-Gehrer [28]	2019	Switzerland	115	66	51	CRS	Caffeine	150	TDS	Tea
Hayashi [29]	2019	Japan	46	77	26	CRS	Caffeine	100	TDS	Water
Bozkurt Koseoglu [30]	2020	Turkey	113	29	0	CS	Caffeine	100	TDS	No intervention
Güngördük [31]	2020	Turkey	96	60	0	GS	Caffeine	150	TDS	Water
Kanza Gül [32]	2021	Turkey	80	28	0	CS	Decaf	NR	TDS	No intervention
Parnasa [33]	2021	Israel	70	56	50	CRS	Caffeine	50 *	TDS	Placebo

Table 1. The characteristics of the included studies.

CRS, colorectal surgery; CS, caesarean section; GS, gynecological surgery; No., number; NR, not reported; TDS, three times per day. * 100 mg of caffeine citrate.

The risk of bias is shown in Table 2 and Appendices D and E. In terms of the overall risk of bias for the time to first defecation, there were concerns about the risk of bias for most studies (11/13), with two of these assessed as having a high risk of bias [25,26].

Table 2. Risk of bias for the eligibility studies for the time to first defecation.

	Risk of Bias 2 Tool Assessment									
Authors [Ref. No.]	Bias Arising from the Randomization Process	Bias Due to Deviations from Intended Interventions	Bias Due to Missing Outcome Data	Bias in the Measurement of the Outcome	Bias in the Selection of the Reported Results	Overall Risk of Bias				
Müller [21]	Low	Some concerns	Some concerns	Some concerns	Some concerns	Some concerns				
Dulskas [22]	Some concerns	Some concerns	Some concerns	Some concerns	Some concerns	Some concerns				
Piric [23]	Some concerns	Some concerns	Some concerns	Some concerns	Some concerns	Some concerns				
Göymen [24]	Some concerns	Low	Low	Some concerns	Some concerns	Some concerns				
Güngördük [25]	Some concerns	Low	Low	Some concerns	High	High				
Mohamed [26]	Some concerns	High	High	Some concerns	Some concerns	High				
Rabiepoor [27]	Some concerns	Low	Low	Some concerns	Some concerns	Some concerns				
Hasler-Gehrer [28]	Low	Some concerns	Some concerns	Some concerns	Low	Some concerns				
Hayashi [29]	Low	Low	Low	Some concerns	Low	Some concerns				
Bozkurt Koseoglu [30]	Low	Some concerns	Some concerns	Some concerns	Low	Some concerns				
Güngördük [31]	Low	Some concerns	Some concerns	Some concerns	Low	Some concerns				
Kanza Gül [32]	Low	Low	Low	Some concerns	Some concerns	Some concerns				
Parnasa [33]	Low	Some concerns	Some concerns	Some concerns	Low	Some concerns				

Table 3 summarizes the findings of the GRADE approach. The certainty of the evidence was low to moderate due to the high risk of bias and inconsistency.

	~	
Table 3.	Summary	of findings.

	Effect of Postoperative Coffee Consumption after Abdominal Surgery								
Patient: Adults after Abdominal Surgery; Setting: In-Patients; Intervention: Coffee; Comparison: Control									
Outcomes	Anticipated Abso C	lute Effects * (95% CI)	Relative Effect	Patient	Certainty of	_			
	Risk with control	Risk with coffee	(95% CI)	(Studies)	(GRADE)	Comments			
Time to first defecation	The median time was 42 h.	MD -10 h (-14 to -5.6)	-	1209 (13 RCTs)	Moderate ^a	Coffee reduced the time to first defecation.			
Length of hospital stay	The median stay was 6 days.	MD -1.5 days (-2.7 to -0.3)	-	905 (9 RCTs)	Low ^{a,b}	Coffee reduced the length of hospital stay.			
Postoperative ileus	165 per 1000.	69 per 1000 (43 to 114)	RR 0.42 (0.26 to 0.69)	913 (8 RCTs)	Low ^{a,b}	Coffee reduced postoperative ileus.			

Effect of Postoperative Coffee Consumption after Abdominal Surgery									
Patient: Adults after Abdominal Surgery; Setting: In-Patients; Intervention: Coffee; Comparison: Control									
Outcomes	Anticipated Abso C	lute Effects * (95% TI)	Relative Effect	Patient	Certainty of	_			
	Risk with control	Risk with coffee	(95% CI)	(Studies)	(GRADE)	Comments			
Time to first flatus	The median time was 30 h.	MD -4.3 h (-8.5 to -0.07)	-	1113 (12 RCT)	Low ^{a,b}	Coffee reduced the time to first flatus.			
Time to first bowel sound	The median time was 10 h.	MD -4.3 h (-7.1 to -1.5)	-	683 (6 RCTs)	Very low ^{a,b,c}	Coffee reduced the time to first bowel sound.			
Time to tolerance of solid food	The median time was 48 h.	MD -9.9 h (-14 to -5.9)	-	833 (8 RCTs)	Low ^{a,b}	Coffee reduced the time to first tolerance of solid food.			

Table 3. Cont.

CI, confidence interval; MD, mean difference; RR, risk ratio. * The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). GRADE Working Group grades of evidence; High certainty: We are very confident that the true effect lies close to that of the estimated effect. Moderate certainty: We are moderately confident in the estimated effect. The true effect is likely to be close to the estimated effect, but there is a possibility that it is substantially different. Low certainty: We have very little confidence in the estimated effect. The true effect is likely to be close to the estimated effect. The true effect from the estimated effect. Very low certainty: We have very little confidence in the estimated effect. The true effect is likely to be substantially different from the estimated effect. ^a Downgraded because of a high risk of bias. ^b Downgraded because of inconsistency due to substantial heterogeneity. ^c Downgraded because of imprecision due to the small sample size.

3.1. Primary Outcomes

3.1.1. Time to First Defecation (Hours)

Coffee reduced the time to first defecation after colorectal surgery (MD -15.37 h; 95% CI = -18.0 to -12.75; I² = 0%) and gynecological surgery (MD -12.83 h; 95% CI = -22.44 to -3.23; I² = 92%) but not after cesarean section (MD -4.79 h, 95% CI = -10.32 to 0.74; I² = 94%) (Figure 2).

		Coffee		0	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
1.1.1 Colorectal surgery									
Müller 2012	60.4	21.3	40	74	21.6	39	6.8%	-13.60 [-23.06, -4.14]	
Piric 2015	80.93	6.892	28	96.2	4.417	30	9.4%	-15.27 [-18.27, -12.27]	+
Dulskas 2015	81	37.1772	60	99.36	27.6	30	5.2%	-18.36 [-32.00, -4.72]	
Hasler-Gehrer 2019	65.2	55.93	56	74.1	52.51	59	3.4%	-8.90 [-28.75, 10.95]	
Hayashi 2019	55.1	27.01	23	69.7	27.65	23	4.4%	-14.60 [-30.40, 1.20]	
Parnasa 2021	51.3	16.89	30	69.8	19.74	28	6.8%	-18.50 [-27.99, -9.01]	
Subtotal (95% CI)			237			209	36.1%	-15.37 [-18.00, -12.75]	•
Heterogeneity: Tau ² = 0.00); Chi² =	1.16, df=	5 (P =	0.95); I ² =	:0%				
Test for overall effect: Z = 1	11.48 (F	o < 0.0000	1)						
4 4 2 6									
1.1.2 Cesarean section						50			
Goymen 2016	12.93	1.9	25	14.305	2.4573	50	9.8%	-1.38 [-2.38, -0.37]	
Rabiepoor 2018	37.22	16.31	50	36.82	16.35	50	8.2%	U.40 [-6.00, 6.80]	
Mohamed 2018	24.5	7.5	97	37.5	11.5	98	9.5%	-13.00 [-15.72, -10.28]	Ŧ
Bozkurt Koseoglu 2020	20.7	11.5	51	29.1	14.3	52	8.8%	-8.40 [-13.41, -3.39]	-
Kanza Gul 2021	34	9.5	40	35	6.75	40	9.3%	-1.00 [-4.61, 2.61]	A
Subiotal (95% CI)			203			290	43.0%	-4.79 [-10.52, 0.74]	•
Heterogeneity: Tau* = 35.5	9; Chr	= 68.30, d	f = 4 (P)	< 0.0000	J1); I* = 9-	4%			
l est for overall effect: $Z = 1$	1.70 (P :	= 0.09)							
1.1.3 Gynecological surge	erv								
Gündördük 2017	47	6.8	58	59.8	14.6	56	91%	-17 80 6-22 01 -13 591	-
Güngördük 2020	30	8	49	38	9.75	47	9 3 96	-8 00 I-11 58 -4 421	-
Subtotal (95% CI)	00		107	00	0.10	103	18.3%	-12.83 [-22.44, -3.23]	•
Heterogeneity: Tau ² = 44 (15: Chi⁼	= 12.11 d	f = 1 (P	= 0.0005	n: F= 92'	36			-
Test for overall effect: Z = 2	2.62 (P :	= 0.009)							
		,							
Total (95% CI)			607			602	100.0%	-10.06 [-14.54, -5.57]	◆
Heterogeneity: Tau ² = 53.0)3; Chi ²	= 191.13,	df = 12	(P < 0.00)001); I ^z =	94%			
Test for overall effect: Z = 4	1.40 (P	< 0.0001)							-100 -50 0 50 100 Equate [coffee] Equate [control]
Test for subgroup differen	ces: Ch	i ² = 11.49,	df = 2	(P = 0.00)	3), l ² = 82	.6%			Favours [conce] Favours [control]

Figure 2. Forest plot of the time to first defecation.

Coffee reduced LOS after gynecological surgery (MD -1.08 d; 95% CI = -1.63 to -0.54; I² = 0%) but not after colorectal surgery (MD -1.78 d; 95% CI = -4.31 to 0.75; I² = 99%) and cesarean section (MD -0.30 d; 95% CI = -0.70 to 0.10; I² = 93%) (Figure 3).





3.1.3. POI

Coffee reduced POI incidence after cesarean section (RR 0.32; 95% CI = 0.14 to 0.72) and gynecological surgery (RR 0.25; 95% CI = 0.13 to 0.48; $I^2 = 0\%$) but not after colorectal surgery (RR 0.81; 95% CI = 0.40 to 1.63; $I^2 = 0\%$) (Figure 4).

	Coffe	ee	Cont	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
1.3.1 Colorectal surgery							
Müller 2012	6	40	10	39	20.9%	0.58 [0.24, 1.45]	
Piric 2015	1	28	0	30	2.3%	3.21 [0.14, 75.61]	
Dulskas 2015	3	60	1	30	4.4%	1.50 [0.16, 13.82]	
Hasler-Gehrer 2019	3	56	3	59	8.6%	1.05 [0.22, 5.00]	
Parnasa 2021 Subtotal (95% CI)	1	32 216	1	31 189	3.0% 39.1%	0.97 [0.06, 14.82] 0.81 [0.40, 1.63]	•
Total events	14		15				
Heterogeneity: Tau ^z = 0.00); Chi ⁼ = '	1.66, df	= 4 (P =	0.80); P	²=0%		
Test for overall effect: Z = I	0.59 (P =	0.56)					
132 Cospress section							
Mohamed 2018	7	97	22	98	25.1%	0 32 10 14 0 721	
Rozkut Koseoglu 2020		51	22	52	23.170	Not estimable	
Subtotal (95% CI)	0	148	0	150	25.1%	0.32 [0.14, 0.72]	•
Total events	7		22			. , ,	
Heterogeneity: Not applica	able .						
Test for overall effect: Z = :	2.77 (P =	0.006)					
1.3.3 Gynecological surge	ery						
Güngördük 2017	8	58	29	56	30.6%	0.27 [0.13, 0.53]	
Güngördük 2020	1	49	7	47	5.1%	0.14 [0.02, 1.07]	
Subtotal (95% CI)		107		103	35.8%	0.25 [0.13, 0.48]	◆
Total events	9		36				
Heterogeneity: Tau ² = 0.00); Chi ² = I	0.37, df	= 1 (P =	0.54); P	² = 0%		
Test for overall effect: Z = -	4.16 (P <	0.0001)				
Total (95% CI)		471		442	100.0%	0.42 [0.26, 0.69]	◆
Total events	30		73				
Heterogeneity: Tau ² = 0.07	?; Chi ² = 3	8.25, df	= 7 (P =	0.31); P	²= 15%		
Test for overall effect: Z = 3	3.49 (P =	0.0005)				Eavours [coffee] Eavours [control]
Test for subaroup differen	ces: Chi ²	$^{2} = 6.24$	df = 2 (F)	P = 0.04), $ ^2 = 68.1$	0%	. arears [concel arears [connel]

Figure 4. Forest plot of postoperative ileus.

3.2. Secondary Outcomes

3.2.1. Time to First Flatus (Hours)

Coffee reduced the time to first flatus after abdominal surgery (MD -4.27 h; 95% CI = -8.28 to -0.26; I² = 96%) (Figure A1). There was no statistically significant difference between colorectal surgery, cesarean section, or gynecological surgery in the subgroup test (p = 0.36).

3.2.2. Time to First Bowel Sound (Hours)

Coffee reduced the time to first flatus after gynecological surgery (MD -8.87 h; 95% CI = -14.65 to -3.09; I² = 86%) but not after cesarean section (MD -1.87 h; 95% CI = -4.40 to 0.66; I² = 93%) (Figure A2).

3.2.3. Time to Tolerance of Solid Food (Hours)

Coffee reduced the time to tolerance of solid food after colorectal surgery, cesarean section, and gynecological surgery (MD -10.11 h; 95% CI = -14.26 to -5.95; I² = 95%) (Figure A3).

3.2.4. Complications/Adverse Events

There have been no reports of adverse events related to postoperative coffee consumption. Coffee did not increase the risk of complications or adverse events after colorectal surgery (RR 0.85; 95% CI = 0.48 to 1.51; $I^2 = 40\%$) and cesarean section (RR 0.80; 95% CI = 0.23 to 2.81). Coffee decreases complications after gynecological surgery (RR 0.27; 95% CI = 0.13 to 0.53) (Figure A4).

3.3. Additional Analyses

In subgroup analyses of caffeinated vs. decaffeinated coffee (Figures A5–A11), there were statistically significant differences between caffeinated and decaffeinated coffee for the time to first defecation (p = 0.02) and the time to tolerance of solid food (p = 0.04). However, when analyzed by surgery type, there were no statistically significant differences between caffeinated and decaffeinated coffee for the time to first defecation after colorectal surgery (p = 0.14) or cesarean section (p = 0.51) (Figure A12) or for the time to tolerance of solid food after cesarean section (p = 0.35) (Figure A13). The results of the sensitivity analysis, excluding studies using imputed statistics, were consistent with the original results except for the time to first flatus (Figures A14–A16).

Regarding publication bias, the funnel plots were symmetric, suggesting a no-potentialno-publication bias (Figure A17).

4. Discussion

This systematic review and meta-analysis demonstrated that postoperative coffee consumption likely reduces the time to first defecation, LOS, and POI after abdominal surgery. This trend is similar to the trends after colorectal and gynecological surgeries. Additionally, there was no difference in LOS and POI between caffeinated and decaffeinated coffee intake. This updated evidence is beneficial to both patients and surgeons regarding the practical endpoints of LOS and POI.

In previous systematic reviews [12–15], coffee accelerated the postoperative recovery of gastrointestinal function but did not reduce POI and LOS. The present review in 13 RCTs with 1246 patients extends the findings of previous reviews, showing a novel benefit of coffee for POI and LOS, in addition to standard ERPs. Preventing POI and shortening LOS can potentially affect the quality of life of patients and reduce their social costs by approximately 40–50% per patient [4–6]. In addition, preventing POI and shortening LOS has the potential to reduce hospital expenditures by US\$750 million per year [4,5]. On average, the incidence of POI was 60% lower in the coffee group (POI: 6.9%) than in the non-coffee control group (16.5%). With postoperative coffee consumption, LOS was reduced by 1.5 days. Given that other consensus data show that ERPs reduce morbidity (RR 0.78) and LOS (-3.1 days) and opioid antagonists, which are frequently used to improve the postoperative course, reduce POI (32%) and LOS (-0.3 days) [34,35], the improved POI and LOS following coffee intake appear to be meaningful in the clinical setting.

The mechanism underlying the effect of coffee on POI is not fully understood. The factors may be caffeine and other substances in coffee, mainly phenolic antioxidants of chlorogenic acid [36]. Caffeine acts positively on inflammation, activating ryanodine-sensitive Ca²⁺ channels by releasing Ca²⁺ from the sarcoplasmic reticulum and inhibiting cyclic guanosine monophosphate degradation, thereby promoting nitric oxide synthesis in the endothelium and enhancing caffeine-induced endothelium-dependent vasodilation [37–39]. Caffeine promotes postoperative recovery of gastrointestinal function through vasodilation [32,40]. Chlorogenic acid has beneficial effects on inflammation and pain [41]. Chlorogenic acid has an anti-inflammatory effect by potently inhibiting the production of tumor necrosis factor- α and interleukin-6 by peripheral blood mononuclear cells [42,43]. In addition, chlorogenic acid inhibits edema formation leading to pain and improves pain following inflammatory responses [42]. These effects may prevent POI and/or lead to shorter LOS.

There were no differences in the recovery of postoperative gastrointestinal function between caffeinated and decaffeinated coffee. These results suggest that caffeine and noncaffeine substances may have a positive effect on POI. In previous studies, both caffeinated and decaffeinated coffee similarly reduced the risk of various cancers and death from all causes [44,45]. The results of our study were in accordance with those of previous studies. However, caution should be exercised when interpreting the results due to the small number of studies involving decaffeinated coffee.

In the present review, there were no reports of adverse events related to coffee, although the caffeine group had a higher postoperative systolic blood pressure (mean 120 mmHg) than that of the control group (mean 100 mmHg) [32,46]. The amount of coffee used in this study was a common amount, and considering the safety of coffee, which is widely used, it is not a phenomenon that should be of great concern [47]. Whether hypertensive patients need to refrain from coffee consumption after surgery requires further study.

Our study showed that the certainty of the evidence was low to moderate because of the high risk of bias and inconsistency based on the GRADE approach. The overall risk of bias was high because the concealment of the allocation sequence was unclear, and the outcomes of interest, POI and LOS, were not included in the protocol. Further studies are needed to clarify allocation concealment and clarify outcomes, such as POI and LOS, in protocols. Additionally, the definitions of POI and LOS were unclear and may be affected by blinding and socioeconomic confounds. In the present review, many studies reported that POI was the indication for reinsertion of the nasogastric tube. POI and LOS should be clearly defined and recorded by blinded outcome assessors. When interpreting our results, heterogeneity in variables such as age, comorbidities, and surgical invasiveness in each population undergoing the procedure should be considered. In the case of cesarean section, the impact of coffee on LOS after cesarean section may be small because the hospital stay is short to begin with [48,49]. In the case of colorectal surgery, coffee had a relatively weak effect on POI, which may be due to other factors related to POI, such as postoperative exercise and nutrition [35,50].

This review has additional limitations. First, the dose–response relationship between coffee consumption and outcomes was not evaluated. In the studies included in this review, the amount of coffee consumed was 100–150 mL, three times per day over 10–20 min. Second, the characteristics of coffee consumers, such as the relationship between regular and non-regular coffee drinkers, have not been clearly reported. Third, our results may not be generalizable to all populations because the compounds in coffee may vary by region, bean type, roast, and brewing method. Furthermore, none of the studies included data collected from children or low-income countries.

5. Conclusions

The findings of this updated systematic review and meta-analysis indicate that postoperative coffee consumption, with or without caffeine consumption, may reduce POI and LOS after colorectal surgery, cesarean section, and gynecological surgery. The findings suggest that patients and surgeons should preferably use postoperative coffee to reduce POI. More RCTs are needed to verify the effect of postoperative coffee consumption because the evidence for its consumption is limited by variations in surgeries.

Author Contributions: Conceptualization, J.W. and K.K.; methodology, J.W., A.M. and K.K.; software, J.W. and A.M.; validation, J.W., A.M. and K.K.; formal analysis, J.W. and A.M.; investigation, J.W., A.M., M.K., K.K. and N.S.; resources, J.W., data curation, J.W., A.M. and K.K; writing—original draft preparation, J.W.; writing—review and editing, A.M., M.K., K.K. and N.S; visualization, J.W. and A.M.; supervision, A.M., M.K., K.K. and N.S.; project administration, M.K., K.K. and N.S.; funding acquisition, J.W. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by JSPS KAKENHI Grant Number JP21K21121.

Institutional Review Board Statement: As this review did not involve animals, neither ethical review board approval nor patient consent was required.

Informed Consent Statement: Not applicable.

Data Availability Statement: All data relevant to the study are included in the article.

Acknowledgments: We thank Kentaro Hayashi from the University of Tokyo, Paul Karanicolas from the Sunnybrook Health Sciences Centre, and Noam Shussman from the Hadassah Hebrew University Medical Center for providing us with the additional information necessary for this study.

Conflicts of Interest: The authors declare no conflict of interest in association with the present study.

Appendix A

Section and Topic	Item	Checklist Item	Location Where Item Is Reported
		TITLE	
Title	1	Identify the report as a systematic review.	1
		ABSTRACT	
Abstract	2	See PRISMA 2020 for the Abstract checklist.	1
		INTRODUCTION	
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	1
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	2
		METHODS	
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	2
Information sources	6	Specify all databases, registers, websites, organizations, reference lists, and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	2
Search strategy	7	Present the full search strategies for all databases, registers, and websites, including any filters and limits used.	Appendices B and C

Table A1. PRISMA 2020 Checklist.

Section and Topic	Section and Topic Item Checklist Item		Location Where Item Is Reported
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved; whether they worked independently; and if applicable, details of automation tools used in the process.	2, 3
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report; whether they worked independently; any processes for obtaining or confirming data from study investigators; and if applicable, details of automation tools used in the process.	2, 3
	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g., for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	2, 3
Data items	10b	List and define all other variables for which data were sought (e.g., participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	2, 3
Study risk-of-bias assessment	11	Specify the methods used to assess the risk of bias in the included studies, including details of the tool(s) used; how many reviewers assessed each study and whether they worked independently; and if applicable, details of automation tools used in the process.	2, 3
Effect measures	12	Specify for each outcome the effect measure(s) (e.g., risk ratio, mean difference) used in the synthesis or presentation of results.	2, 3
	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g., tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	2, 3
-	13b	Describe any methods required to prepare the data for presentation; synthesis, such as handling of missing summary statistics; or conversions.	2, 3
Synthesis methods	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	2, 3
-	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	2, 3
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g., subgroup analysis, meta-regression).	2, 3
	13f	Describe any sensitivity analyses conducted to assess the robustness of the synthesized results.	2, 3
Reporting bias assessment	14	Describe any methods used to assess the risk of bias due to missing results in a synthesis (arising from reporting biases).	3
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	3

Table A1. Cont.

Table A1. Cont.

Section and Topic	Item	Location Where Item Is Reported		
		RESULTS		
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	3	
	16b	Cite studies that might appear to meet the inclusion criteria but were excluded and explain why they were excluded.	3	
Study characteristics	17	Cite each included study and present its characteristics.	4	
Risk of bias in studies	18	Present assessments of the risk of bias for each included study.	4, Table 2, Appendices D and E	
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g., confidence/credible interval), ideally using structured tables or plots.	4, Table 1	
	20a	For each synthesis, briefly summarize the characteristics and the risk of bias among contributing studies.	5, 6, 7, 8	
Results of syntheses	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g., confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	5, 6, 7, 8	
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	5, 6, 7, 8	
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	8	
Reporting biases	21	Present assessments of the risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	8	
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	Table 3	
		DISCUSSION		
	23a	Provide a general interpretation of the results in the context of other evidence.	8	
Discussion	23b	Discuss any limitations of the evidence included in the review.	9	
	23c	Discuss any limitations of the review processes used.	9	
	23d	Discuss implications of the results for practice, policy, and future research.	9	
	OT	HER INFORMATION		
	24a	Provide registration information for the review, including the register name and the registration number, or state that the review was not registered.	2	
Registration and protocol	24b	Indicate where the review protocol can be accessed or state that a protocol was not prepared.	2	
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	2	
Support	25	Describe sources of financial or non-financial support for the review and the role of the funders or sponsors in the review.	9	
Competing interests	26	Declare any competing interests of review authors.	10	
Availability of data, code, and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms, data extracted from included studies, data used for all analyses, analytic code, and any other materials used in the review.	24, 25, 26	

Appendix B. Search Strategy for Electronic Databases

MEDLINE (PubMed) search strategy

#1. ("coffee" [Mesh] OR "coffee" [tiab]) OR ("caffeine" [Mesh] OR "caffeine" [tiab])

#2. ("abdomen" [Mesh] OR "abdomen" [tiab] OR "abdominal" [tiab]) OR ("surgical procedures, operative" [Mesh] OR "surgical" OR "producer" OR "operation" OR "operative")

#3. #1 AND #2

#4. (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR drug therapy[sh] OR placebo [tiab] OR randomly[tiab] OR trial[tiab] OR groups[tiab]) NOT (animals [mh] NOT humans [mh])

#5. #3 AND #4

CENTRAL (Cochrane Library) search strategy

([mh coffee] OR coffee:ti,ab OR ([mh caffeine] OR caffeine:ti,ab)) AND ([mh abdomen] OR abdomen:ti,ab OR abdominal:ti,ab OR ([mh "surgical procedures, operative"] OR surgical OR producer OR operation OR operative))

EMBASE (Dialog) search strategy

S1 (EMB.EXACT.EXPLODE("coffee") OR (ab("coffee") OR ti("coffee")) OR EMB.EXACT.EXPLODE("caffeine") OR (ab("caffeine") OR ti("caffeine")))

S2 EMB.EXACT.EXPLODE("abdomen") OR (ab("abdomen") OR ti("abdomen")) OR (ab("abdominal") OR ti("abdominal")) OR (EMB.EXACT.EXPLODE("abdominal surgery")) OR (ab("surgical") OR ti("surgical")) OR (ab("producer") OR ti("producer")) OR (ab("operation")) OR (ab("operative")) OR ti("operative"))

\$3 \$1 AND \$2

S4 (ab(random*) OR ti(random*)) OR (ab(placebo*) OR ti(placebo*)) OR (ab(double NEAR/1 blind*) OR ti(double NEAR/1 blind*))

S5 S3 AND S4

Appendix C. Search Strategy for Clinical Trial Registries

ICTRP search strategy

(Coffee OR Caffeine) AND (abdomen OR abdominal OR surgical OR producer OR operation OR operative)

ClinicalTrials.gov search strategy

Condition or disease: (abdomen OR abdominal OR surgical OR producer OR operation OR operative)

Intervention: Coffee OR Caffeine

Appendix D

Table A2. Risk of Bias for Eligibility Studies for the Length of Hospital Stay.

	Risk of Bias 2 Tool Assessment									
Authors [Ref No.]	Bias Arising from the Randomization Process	Bias Due to Deviations from Intended Interventions	Bias Due to Missing Outcome Data	Bias in the Measurement of the Outcome	Bias in the Selection of the Reported Results	Overall Risk of Bias				
Müller [20]	Low	Some concerns	Some concerns	Some concerns	Some concerns	Some concerns				
Dulskas [21]	Some concerns	Some concerns	Some concerns	Some concerns	Some concerns	Some concerns				
Piric [22]	Some concerns	Some concerns	Some concerns	Some concerns	Some concerns	Some concerns				
Güngördük [24]	Some concerns	Low	Low	Some concerns	High	High				
Mohamed [25]	Some concerns	High	High	Some concerns	Some concerns	High				
Rabiepoor [26]	Some concerns	Low	Low	Some concerns	Some concerns	Some concerns				
Hasler-Gehrer [27]	Low	Some concerns	Some concerns	Some concerns	High	High				
Hayashi [28]	Low	Low	Low	Some concerns	Low	High				
Güngördük [30]	Low	Some concerns	Some concerns	Some concerns	High	High				
Parnasa [32]	Low	Some concerns	Some concerns	Some concerns	Low	Some concerns				

Appendix E

Table A3. Risk of Bias for the Eligibility Studies for Postoperative Ileus.

	Risk of Bias 2 Tool Assessment									
Authors [Ref No.]	Bias Arising from the Randomization Process	Bias Due to Deviations from Intended Interventions	Bias Due to Missing Outcome Data	Bias in the Measurement of the Outcome	Bias in the Selection of the Reported Results	Overall Risk of Bias				
Müller [20]	Low	Some concerns	Some concerns	Some concerns	Some concerns	Some concerns				
Dulskas [21]	Some concerns	Some concerns	Some concerns	Some concerns	Some concerns	Some concerns				
Piric [22]	Some concerns	Some concerns	Some concerns	Some concerns	Some concerns	Some concerns				
Güngördük [24]	Some concerns	Low	Low	Some concerns	High	High				
Mohamed [25]	Some concerns	High	High	Some concerns	Some concerns	High				
Hasler-Gehrer [27]	Low	Some concerns	Some concerns	Some concerns	High	High				
Bozkurt Koseoglu [29]	Low	Some concerns	Some concerns	Some concerns	High	High				
Güngördük [30]	Low	Some concerns	Some concerns	Some concerns	High	High				
Parnasa [32]	Low	Some concerns	Some concerns	Some concerns	High	High				

	0	offee		C	Control			Mean Difference	Mean Difference
Study or Subgroup	Mean	\$D	Total	Mean	\$D	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
2.1.1 Colorectal surgery									
Müller 2012	40.6	16.1	40	46.4	20.1	39	6.8%	-5.80 [-13.84, 2.24]	
Dulskas 2015	36.4835	16.009	60	42.48	20.1	30	6.7%	-6.00 [-14.25, 2.26]	
Hasler-Gehrer 2019	40	5.75	56	31	5.25	59	9.1%	9.00 [6.98, 11.02]	*
Hayashi 2019	9.3	9.4	23	12.6	12.5	23	7.5%	-3.30 [-9.69, 3.09]	
Parnasa 2021	51.3	10.11	30	57.3	8.93	28	8.1%	-6.00 [-10.90, -1.10]	-
Subtotal (95% CI)			209			179	38.1%	-2.11 [-10.60, 6.39]	•
Heterogeneity: Tau ^z = 83.9	91; Chi ^z = 1	54.69, df	= 4 (P <	< 0.0000	01); I₹=	93%			
Test for overall effect: Z =	0.49 (P = 0).63)							
2.1.2 Cesarean section									
Göymen 2016	7	1.46	25	15.21	5.58	50	9.1%	-8.21 [-9.86, -6.56]	-
Mohamed 2018	17.6	8.5	97	28.5	10.7	98	8.9%	-10.90 [-13.61, -8.19]	-
Rabiepoor 2018	17.28	4.44	50	22.54	5.09	50	9.1%	-5.26 [-7.13, -3.39]	•
Bozkurt Koseoglu 2020	8.6	3.3	51	11.3	7.5	52	9.0%	-2.70 [-4.93, -0.47]	1
Kanza Gul 2021	39	14.75	40	33.2	8.375	40	8.0%	5.80 [0.54, 11.06]	
Subtotal (95% CI)			203			290	44.170	-4.80 [-8.43, -1.17]	•
Heterogeneity: Tau* = 15.1	J4; Chi* = }	47.70, df	= 4 (P <	< 0.0000	J1); F=	92%			
lest for overall effect: $\angle =$	2.59 (P = t).010)							
2.1.3 Gynecological surg	егу								
Güngördük 2017	29.7	4.9	58	41.6	10.9	56	8.8%	-11.90 [-15.02, -8.78]	-
Güngördük 2020	19	5.5	49	25	6.75	47	9.0%	-6.00 [-8.47, -3.53]	-
Subtotal (95% CI)			107			103	17.7%	-8.87 [-14.65, -3.09]	◆
Heterogeneity: Tau ² = 15.3	34; Chi⁼ = i	8.44, df =	1 (P =	0.004); [l [≈] = 88%				
Test for overall effect: Z =	3.01 (P = 0	0.003)							
Total (95% CI)			579			572	100.0%	-4.27 [-8.28, -0.26]	◆
Heterogeneity: Tau ² = 45.1	07; Chi ≊ = 1	254.16, d	f=11 (P < 0.00	0001); I ^z	= 96%			
Test for overall effect: Z = 3	2.09 (P = 0	0.04)							Favours [coffee] Favours [control]
Test for subgroup differen	ces: Chi r :	= 2.06, df	= 2 (P	= 0.36),	$ ^2 = 3.0^{\circ}$	%			

Figure A1. Forest plot of the time to first flatus.

	(Coffee		(Control			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
2.2.2 Cesarean section									
Göymen 2016	5.33	96.25	25	6.583	1.6888	50	0.5%	-1.25 [-38.99, 36.48]	
Rabiepoor 2018	5.84	1.41	50	6.16	1.33	50	21.9%	-0.32 [-0.86, 0.22]	+
Mohamed 2018	10.5	3.6	97	15.2	4.8	98	21.3%	-4.70 [-5.89, -3.51]	-
Bozkurt Koseoglu 2020	5.7	3.4	51	6.4	2.7	52	21.3%	-0.70 [-1.89, 0.49]	t
Subtotal (95% CI)			223			250	65.0%	-1.87 [-4.40, 0.66]	•
Heterogeneity: Tau ² = 4.7	6; Chi ² =	43.53,	df = 3 (P < 0.00	1001); F =	= 93%			
Test for overall effect: Z =	1.45 (P =	= 0.15)							
2.2.3 Gynecological surg	егу								
Güngördük 2017	35.6	5.4	58	47.5	11.7	56	16.7%	-11.90 [-15.26, -8.54]	+
Güngördük 2020	22	5.75	49	28	7.75	47	18.2%	-6.00 [-8.74, -3.26]	*
Subtotal (95% CI)			107			103	35.0%	-8.87 [-14.65, -3.09]	◆
Heterogeneity: Tau ² = 14.	96; Chi²	= 7.10,	df = 1 (P = 0.00	18); I ^z = 8	6%			
Test for overall effect: Z =	3.01 (P =	= 0.003)							
Total (95% CI)			330			353	100.0%	-4.31 [-7.10, -1.52]	•
Heterogeneity: Tau ² = 9.1	5; Chi ² =	94.54,	df = 5 (P < 0.00	1001); F=	= 95%			
Test for overall effect: Z =	3.03 (P =	= 0.002)							Favours [coffee] Favours [control]
Test for subgroup differen	nces: Ch	i ² = 4.73	2, df = 1	(P = 0.)	03), I ² = 7	8.8%			



		Coffee		0	Control			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% CI
2.3.1 Colorectal surgery									
Müller 2012	49.2	21.3	40	55.8	30	39	8.0%	-6.60 [-18.10, 4.90]	
Dulskas 2015	53.4	22.9864	60	67.2	30	30	7.4%	-13.80 [-26.01, -1.59]	
Parnasa 2021	93.6	18.59	30	109.6	19.44	28	9.6%	-16.00 [-25.80, -6.20]	
Subtotal (95% CI)			130			97	25.0%	-12.52 [-18.89, -6.16]	•
Heterogeneity: Tau ² = 0.00	0; Chi ^z =	1.54, df =	2 (P =	0.46); l²	= 0%				
Test for overall effect: Z = 3	3.86 (P =	= 0.0001)							
0.0.0.0									
2.3.2 Cesarean section									
Mohamed 2018	18.6	8.1	97	29.5	10.6	98	19.0%	-10.90 [-13.55, -8.25]	*
Rabiepoor 2018	13.1	1.9	50	12.84	1.76	50	20.4%	0.26 [-0.46, 0.98]	-
Bozkurt Koseoglu 2020	8.78	2.33	51	12.88	2.6	52	20.4%	-4.10 [-5.05, -3.15]	
Subtotal (95% CI)			198			200	59.8%	-4.72 [-9.30, -0.13]	•
Heterogeneity: Tau* = 15.	70; Chif	= 99.40, d	t = 2 (P	< 0.000	JU1); F=	= 98%			
Test for overall effect: $Z = 1$	2.02 (P =	= U.U4)							
2.3.3 Gynecological surg	еги								
Güngördük 2017	84	28.8	58	115.2	38.4	56	7.2%	-31 20 [-43 69 -18 71]	
Güngördük 2020	48	18	49	72	36	47	8.0%	-24 00 [-35 46 -12 54]	
Subtotal (95% CI)			107			103	15.2%	-27.29 [-35.73, -18.84]	•
Heterogeneity: Tau ² = 0.0(0: Chi ^z =	0.69. df =	1 (P =	0.41); l ^z	= 0%				-
Test for overall effect: Z = 1	6.33 (P	< 0.00001)						
Total (95% CI)			435			400	100.0%	-10.11 [-14.26, -5.95]	•
Heterogeneity: Tau ² = 21.8	84; Chi ^z	= 147.31,	df = 7 (P < 0.00	0001); P	² = 95%			
Test for overall effect: Z =	4.77 (P	< 0.00001))						-100 -50 U 50 100
Test for subgroup differen	ices: Ch	i ² = 21.69	df= 2	(P < 0.0	001), P	= 90.89	6		

Figure A3. Forest plot of the time to toleration of solid food.

.

	Coffe	e	Contr	lor		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% CI
2.4.1 Colorectal surgery							
Müller 2012	8	40	10	39	17.1%	0.78 [0.34, 1.77]	
Piric 2015	4	28	14	30	14.9%	0.31 [0.11, 0.82]	
Dulskas 2015	3	60	1	30	5.4%	1.50 [0.16, 13.82]	
Hayashi 2019	6	23	3	23	11.7%	2.00 [0.57, 7.05]	
Hasler-Gehrer 2019	15	56	15	59	20.1%	1.05 [0.57, 1.95]	
Parnasa 2021	0	32	0	28		Notestimable	
Subtotal (95% CI)		239		209	69.3%	0.85 [0.48, 1.51]	-
Total events	36		43				
Heterogeneity: Tau ² = 0.17	; Chi ² = €	5.68, df	= 4 (P =	0.15); P	²= 40%		
Test for overall effect: $Z = 0$).56 (P =	0.58)					
2 / 2 Cosaroan section							
Debiopoor 2019		60	5	50	11 706	0 00 00 22 2 041	
Rapiepoor 2018	4	50	0	50	11.7 70	0.80 [0.23, 2.81]	-
Subtotal (95% CI)	0	101	0	102	11.7%	0.80 [0.23, 2.81]	
Total events	4		5			0.000[0.120,120.1]	
Heterogeneity: Not applica	hle		5				
Test for overall effect: $7 = 1$	1.35 (P =	0.73)					
		0.10/					
2.4.3 Gynecological surge	ery						
Güngördük 2017	8	58	29	56	19.0%	0.27 [0.13, 0.53]	
Güngördük 2020	0	49	0	47		Not estimable	
Subtotal (95% CI)		107		103	19.0%	0.27 [0.13, 0.53]	◆
Total events	8		29				
Heterogeneity: Not applica	ble						
Test for overall effect: Z = 3	3.75 (P =	0.0002)				
Total (95% CI)		447		414	100.0%	0.68 [0.38, 1.22]	•
Total events	48		77				
Heterogeneity: Tau ² = 0.34	: Chi ² = 1	4.99. d	f = 6 (P =	= 0.02):	l ² = 60%		the state of the s
Test for overall effect: Z = 1	.29 (P =	0.20)					U.U1 0.1 1 10 100
Test for subgroup differen	ces: Chiª	= 6.74	. df = 2 (F	P = 0.03	$, ^2 = 70.$	3%	Favours [conee] Favours [control]

Figure A4. Forest plot of complications/adverse events.

	(Coffee		C	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
3.1.1 Caffeine									
Müller 2012	60.4	21.3	40	74	21.6	39	8.8%	-13.60 [-23.06, -4.14]	
Piric 2015	80.93	6.892	28	96.2	4.417	30	15.5%	-15.27 [-18.27, -12.27]	+
Dulskas 2015	90	36.72	30	99.36	27.6	30	4.5%	-9.36 [-25.80, 7.08]	
Güngördük 2017	42	6.8	58	59.8	14.6	56	14.3%	-17.80 [-22.01, -13.59]	+
Rabiepoor 2018	37.22	16.31	50	36.82	16.35	50	11.9%	0.40 [-6.00, 6.80]	+
Hasler-Gehrer 2019	65.2	55.93	56	74.1	52.51	59	3.3%	-8.90 [-28.75, 10.95]	
Hayashi 2019	55.1	27.01	23	69.7	27.65	23	4.7%	-14.60 [-30.40, 1.20]	
Bozkurt Koseoglu 2020	20.7	11.5	51	29.1	14.3	52	13.4%	-8.40 [-13.41, -3.39]	+
Güngördük 2020	30	8	49	38	9.75	47	14.9%	-8.00 [-11.58, -4.42]	+
Parnasa 2021	51.3	16.89	30	69.8	19.74	28	8.8%	-18.50 [-27.99, -9.01]	
Subtotal (95% CI)			415			414	100.0%	-11.39 [-15.43, -7.35]	•
Heterogeneity: Tau ² = 25.	14; Chi ≃ =	: 35.28,	df= 9 ((P < 0.000	01); I ^z = 7	4%			
Test for overall effect: Z =	5.53 (P <	0.0000	11)						
3.1.2 Decafe									
Dulskas, decafe 2015	72	36	30	96 96	27.6	30	8.6%	-27 36 [-43 59 -11 13]	(
Gövmen decafe 2016	12 93	19	25	14 305	2 4573	50	50.3%	-1 38 [-2 38 -0 37]	
Kanza Gül, decafe 2021	34	9.5	40	35	675	40	41 1 %	-1 00 [-4 61 2 61]	
Subtotal (95% CI)	54	0.0	95	00	0.10	120	100.0%	-3.44 [-8.64, 1.76]	•
Heterogeneity: Tau ² = 13.	72; Chi ^z =	9.87, 0	if = 2 (F	= 0.007)	; I ^z = 809	6			
Test for overall effect: Z =	1.30 (P =	0.19)							
									-100 -30 0 30 100

Test for subgroup differences: Chi² = 5.60, df = 1 (P = 0.02), l² = 82.1%

Figure A5. Forest plot of time to first defecation by coffee types (caffeinated or decaffeinated coffee).

		Coffee		(Control			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
3.2.1 Caffeine									
Müller 2012	10.8	4.4	40	11.3	4.5	39	9.8%	-0.50 [-2.46, 1.46]	
Dulskas 2015	6	0.5804	30	7	1.045	30	11.4%	-1.00 [-1.43, -0.57]	+
Piric 2015	8.607	0.5804	28	16.17	1.045	30	11.4%	-7.56 [-7.99, -7.13]	+
Güngördük 2017	6.1	1.1	58	7.4	2.9	56	11.2%	-1.30 [-2.11, -0.49]	
Rabiepoor 2018	1.25	0.396	50	1.34	0.4925	50	11.5%	-0.09 [-0.27, 0.09]	1
Hasler-Gehrer 2019	6	1	56	7	0.5	59	11.4%	-1.00 [-1.29, -0.71]	+
Hayashi 2019	3.91	2.78	23	3.87	1.22	23	10.8%	0.04 [-1.20, 1.28]	
Güngördük 2020	2.5	1	49	3.4	2.4	47	11.2%	-0.90 [-1.64, -0.16]	
Parnasa 2021	6	1.11	30	7	0.74	28	11.4%	-1.00 [-1.48, -0.52]	+
Subtotal (95% CI)			364			362	100.0%	-1.50 [-3.12, 0.11]	-
Heterogeneity: Tau ² = 5.8	89; Chi²	= 995.02	, df = 8	(P < 0.0	10001); I ^z	= 99%			
Test for overall effect: Z =	= 1.83 (F	= 0.07)							
3.2.2 Decafe									
Dulskas_decafe 2015	7	0.5804	30	7	1.045	30	100.0%	0.00 [-0.43, 0.43]	
Subtotal (95% CI)			30			30	100.0%	0.00 [-0.43, 0.43]	•
Heterogeneity: Not appli	cable								
Test for overall effect: Z =	= 0.00 (F	'= 1.00)							
									-10 -5 0 5 10
									Favours [coffee] Favours [control]
Test for subgroup differe	ences: C	hi ² = 3.13	3, df = 1	(P = 0.0	08), I² = 6	8.0%			

Figure A6. Forest plot of length of hospital stay by coffee types (caffeinated or decaffeinated coffee).

	Coffe	e	Contr	lo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% CI
3.3.1 Caffeine							
Müller 2012	6	40	10	39	27.0%	0.58 [0.24, 1.45]	
Piric 2015	1	28	0	30	4.0%	3.21 [0.14, 75.61]	
Dulskas 2015	2	30	1	30	6.9%	2.00 [0.19, 20.90]	
Güngördük 2017	8	58	29	56	34.6%	0.27 [0.13, 0.53]	
Hasler-Gehrer 2019	3	56	3	59	13.5%	1.05 [0.22, 5.00]	
Bozkurt Koseoglu 2020	0	51	0	52		Not estimable	
Güngördük 2020	1	49	7	47	8.7%	0.14 [0.02, 1.07]	
Parnasa 2021	1	32	1	31	5.3%	0.97 [0.06, 14.82]	
Subtotal (95% CI)		344		344	100.0%	0.51 [0.26, 0.98]	-
Total events	22		51				
Heterogeneity: Tau ² = 0.20	D; Chi ² = 8	3.29, df	= 6 (P =	0.22); P	²= 28%		
Test for overall effect: Z = 3	2.01 (P =	0.04)					
3.3.2 Decafe							⊥_
Dulskas_decafe 2015	1	30	1	30	100.0%	1.00 [0.07, 15.26]	
Subtotal (95% CI)		30		30	100.0%	1.00 [0.07, 15.26]	
Total events	1		1				
Heterogeneity: Not applica	able						
Test for overall effect: Z =	0.00 (P =	1.00)					
							Eavours [coffee] Eavours [control]
Test for subgroup differen	ices: Chi ^z	= 0.22	. df = 1 (F	^o = 0.64), I ² = 0%		

Figure A7. Forest plot of postoperative ileus by coffee types (caffeinated or decaffeinated coffee).

	(Coffee		C	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
3.4.1 Caffeine									
Müller 2012	40.6	16.1	40	46.4	20.1	39	8.1%	-5.80 [-13.84, 2.24]	
Dulskas 2015	37.68	16.1	30	42.48	20.1	30	7.5%	-4.80 [-14.02, 4.42]	+
Göymen 2016	7	1.46	25	15.21	5.58	50	11.1%	-8.21 [-9.86, -6.56]	*
Güngördük 2017	29.7	4.9	58	41.6	10.9	56	10.6%	-11.90 [-15.02, -8.78]	+
Rabiepoor 2018	17.28	4.44	50	22.54	5.09	50	11.0%	-5.26 [-7.13, -3.39]	*
Hasler-Gehrer 2019	40	5.75	56	31	5.25	59	11.0%	9.00 [6.98, 11.02]	*
Hayashi 2019	9.3	9.4	23	12.6	12.5	23	9.1%	-3.30 [-9.69, 3.09]	
Bozkurt Koseoglu 2020	8.6	3.3	51	11.3	7.5	52	10.9%	-2.70 [-4.93, -0.47]	-
Güngördük 2020	19	5.5	49	25	6.75	47	10.9%	-6.00 [-8.47, -3.53]	*
Parnasa 2021	51.3	10.11	30	57.3	8.93	28	9.8%	-6.00 [-10.90, -1.10]	
Subtotal (95% CI)			412			434	100.0%	-4.43 [-8.80, -0.06]	◆
Heterogeneity: Tau ² = 44.3	27; Chi ²∘	= 215.6	7, df = 9	(P < 0.0	00001);	I ² = 96	%		
Test for overall effect: Z =	1.99 (P =	0.05)							
3.4.2 Decafe									
Dulskas_decafe 2015	35.28	16.1	30	42.48	20.1	30	45.6%	-7.20 [-16.42, 2.02]	
Kanza Gül_decafe 2021	39	14.75	40	33.2	8.375	40	54.4%	5.80 [0.54, 11.06]	
Subtotal (95% CI)			70			70	100.0%	-0.13 [-12.82, 12.56]	•
Heterogeneity: Tau ² = 69.1	B5; Chi ≇⊧	= 5.77, 0	#f = 1 (F	P = 0.02)	; I² = 8 3	1%			
Test for overall effect: Z =	0.02 (P =	: 0.98)							
									Favours (coffee) Favours (control)
Toot for outparoup differen	ana: Chi	Z - 0 40	df = 1	(D - 0.5)	23 12 - 1	204			r arcare [cence] r arcare [centrol]

Test for subgroup differences: $Chi^2 = 0.40$, df = 1 (P = 0.53), $I^2 = 0\%$



Study or Subgroup Mean SD Total Mean SD Total Weight IV, Random, 95% CI IV, Random, 95% CI 3.5.1 Caffeine Güngördük 2017 35.6 5.4 58 47.5 11.7 56 21.5% -11.90 [-15.26, -8.54] ■ Rabiepoor 2018 5.84 1.41 50 6.16 1.33 50 28.0% -0.32 [-0.86, 0.22] ■ Bozkurt Koseoglu 2020 5.7 3.4 51 6.4 2.7 52 27.2% -0.70 [-1.89, 0.49] ■ Güngördük 2020 22 5.75 49 28 7.75 47 23.4% -6.00 [-8.74, -3.26] ■ Subtotal (95% CI) 208 205 100.0% -4.24 [-7.43, -1.05] ■ Heterogeneity: Tau ² = 9.39; Chi ² = 58.74, df = 3 (P < 0.00001); I ² = 95% Test for overall effect: Z = 2.60 (P = 0.009) ■ ■
3.5.1 Caffeine Güngördük 2017 35.6 5.4 58 47.5 11.7 56 21.5% -11.90 [-15.26, -8.54] Rabiepoor 2018 5.84 1.41 50 6.16 1.33 50 28.0% -0.32 [-0.86, 0.22] Bozkurt Koseoglu 2020 5.7 3.4 51 6.4 2.7 52 27.2% -0.70 [-1.89, 0.49] Güngördük 2020 22 5.75 49 28 7.75 47 23.4% -6.00 [-8.74, -3.26] Subtotal (95% Cl) 208 205 100.0% -4.24 [-7.43, -1.05] ● Heterogeneity: Tau ² = 9.39; Chi ² = 58.74, df = 3 (P < 0.00001); I ² = 95% Test for overall effect: Z = 2.60 (P = 0.009)
Güngördük 2017 35.6 5.4 58 47.5 11.7 56 21.5% -11.90 [-15.26, -8.54] Rabiepoor 2018 5.84 1.41 50 6.16 1.33 50 28.0% -0.32 [-0.86, 0.22] Bozkurt Koseoglu 2020 5.7 3.4 51 6.4 2.7 52 27.2% -0.70 [-1.89, 0.49] Güngördük 2020 22 5.75 49 28 7.75 47 23.4% -6.00 [-8.74, -3.26] Subtotal (95% Cl) 208 205 100.0% -4.24 [-7.43, -1.05] ● Heterogeneity: Tau ² = 9.39; Chi ² = 58.74, df = 3 (P < 0.00001); I ² = 95% Test for overall effect: Z = 2.60 (P = 0.009) ●
Rabiepoor 2018 5.84 1.41 50 6.16 1.33 50 28.0% -0.32 [-0.86, 0.22] Bozkurt Koseoglu 2020 5.7 3.4 51 6.4 2.7 52 27.2% -0.70 [-1.89, 0.49] Güngördük 2020 22 5.75 49 28 7.75 47 23.4% -6.00 [-8.74, -3.26] Subtotal (95% Cl) 208 205 100.0% -4.24 [-7.43, -1.05] ● Heterogeneity: Tau ² = 9.39; Chi ² = 58.74, df = 3 (P < 0.00001); I ² = 95% Test for overall effect: Z = 2.60 (P = 0.009) ●
Bozkurt Koseoglu 2020 5.7 3.4 51 6.4 2.7 52 27.2% -0.70 [-1.89, 0.49] Güngördük 2020 22 5.75 49 28 7.75 47 23.4% -6.00 [-8.74, -3.26] Subtotal (95% CI) 208 205 100.0% -4.24 [-7.43, -1.05] Heterogeneity: Tau ² = 9.39; Chi ² = 58.74, df = 3 (P ≤ 0.00001); I ² = 95% Test for overall effect: Z = 2.60 (P = 0.009)
Güngördük 2020 22 5.75 49 28 7.75 47 23.4% -6.00 [-8.74, -3.26] ■ Subtotal (95% CI) 208 205 100.0% -4.24 [-7.43, -1.05] ● Heterogeneity: Tau ² = 9.39; Chi ² = 58.74, df = 3 (P < 0.00001); I ² = 95% Test for overall effect: Z = 2.60 (P = 0.009) ●
Subtotal (95% CI) 208 205 100.0% -4.24 [-7.43, -1.05] ♦ Heterogeneity: Tau ² = 9.39; Chi ² = 58.74, df = 3 (P < 0.00001); I ² = 95% Test for overall effect: Z = 2.60 (P = 0.009) ♦
Heterogeneity: Tau² = 9.39; Chi² = 58.74, df = 3 (P < 0.00001); l² = 95% Test for overall effect: Z = 2.60 (P = 0.009)
Test for overall effect: Z = 2.60 (P = 0.009)
3.5.2 Decafe
Göymen_decafe 2016 5.33 96.25 25 6.583 1.6888 50 100.0% -1.25 [-38.99, 36.48]
Subtotal (95% Cl) 25 50 100.0% -1.25 [-38.99, 36.48]
Heterogeneity: Not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
Favours [conffee] Favours [control]

Test for subgroup differences: Chi² = 0.02, df = 1 (P = 0.88), I² = 0%

Figure A9. Forest plot of time to first bowel sound by coffee types (caffeinated or decaffeinated coffee).

	(Coffee		(Control			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
3.6.1 Caffeine									
Müller 2012	49.2	21.3	40	55.8	30	39	9.0%	-6.60 [-18.10, 4.90]	
Dulskas 2015	62.4	21.3	30	67.2	30	30	7.4%	-4.80 [-17.97, 8.37]	
Güngördük 2017	84	28.8	58	115.2	38.4	56	8.0%	-31.20 [-43.69, -18.71]	
Rabiepoor 2018	13.1	1.9	50	12.84	1.76	50	27.8%	0.26 [-0.46, 0.98]	•
Güngördük 2020	48	18	49	72	36	47	9.0%	-24.00 [-35.46, -12.54]	
Bozkurt Koseoglu 2020	8.78	2.33	51	12.88	2.6	52	27.6%	-4.10 [-5.05, -3.15]	-
Parnasa 2021	93.6	18.59	30	109.6	19.44	28	11.1%	-16.00 [-25.80, -6.20]	
Subtotal (95% CI)			308			302	100.0%	-8.46 [-12.65, -4.27]	•
Heterogeneity: Tau ² = 16.3	30; Chi ^z	= 97.60	, df = 6	(P < 0.0	00001);	l ^z = 94%	6		
Test for overall effect: Z =	3.96 (P	< 0.000	1)						
3.6.2 Decafe									
Dulskas_decafe 2015	44.4	21.3	30	67.2	30	30	100.0%	-22.80 [-35.97, -9.63]	
Subtotal (95% CI)			30			30	100.0%	-22.80 [-35.97, -9.63]	●
Heterogeneity: Not applic:	able								
Test for overall effect: Z =	3.39 (P :	= 0.000	7)						
									-100 -50 0 50 100
To al familia di Mana				(D 0	0.0.17	75.00			Favours [coffee] Favours [control]

Test for subgroup differences: Chi² = 4.14, df = 1 (P = 0.04), l² = 75.8%

Figure A10. Forest plot of time to toleration of solid food by coffee types (caffeinated or decaffeinated coffee).

	Coffe	e	Contr	ol		Risk Ratio		Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Rando	om, 95% Cl	
3.7.1 Caffeine										
Müller 2012	8	40	10	39	17.4%	0.78 [0.34, 1.77]				
Piric 2015	4	28	14	30	15.1%	0.31 [0.11, 0.82]				
Dulskas 2015	1	30	1	30	3.8%	1.00 [0.07, 15.26]				
Güngördük 2017	8	58	29	56	19.4%	0.27 [0.13, 0.53]				
Rabiepoor 2018	4	50	5	50	11.8%	0.80 [0.23, 2.81]				
Hayashi 2019	6	23	3	23	11.8%	2.00 [0.57, 7.05]		-		
Hasler-Gehrer 2019	15	56	15	59	20.6%	1.05 [0.57, 1.95]		_	—	
Bozkurt Koseoglu 2020	0	51	0	52		Not estimable				
Güngördük 2020	0	49	0	47		Not estimable				
Parnasa 2021	0	32	0	28		Not estimable				
Subtotal (95% CI)		417		414	100.0%	0.66 [0.37, 1.18]		-		
Total events	46		77							
Heterogeneity: Tau ² = 0.32	2; Chi² = 1	4.54, 0	if = 6 (P =	: 0.02);	I² = 59%					
Test for overall effect: Z = 1	.40 (P =	0.16)								
3.7.2 Decafe										
Dulskas_decafe 2015	2	30	1	30	100.0%	2.00 [0.19, 20.90]			_	
Subtotal (95% CI)		30		30	100.0%	2.00 [0.19, 20.90]				
Total events	2		1							
Heterogeneity: Not applica	able									
Test for overall effect: Z = 0).58 (P =	0.56)								
							L 01		10	100
							0.01	U.I Eavours [coffee]	Favours [control]	100
T 16 1 1 1 1 1 1 1		~ ~ ~	10 4 10					avours [conee]	avours [control]	

Test for subgroup differences: Chi² = 0.80, df = 1 (P = 0.37), l² = 0%

Figure A11. Forest plot of complications/adverse events by coffee types (caffeinated or decaffeinated coffee).

A. Colorectal surgery

		Coffee		C	ontrol			Mean Difference		Mean Difference
Study or Subg	roup Mean	SD	Total	Mean	SD T	Total	Weight	IV, Random, 95% CI		IV, Random, 95% CI
3.8.1 Caffeine										
Müller 2012	60.4	21.3	40	74	21.6	39	7.8%	-13.60 [-23.06, -4.14]		
Piric 2015	80.93	6.892	28	96.2	4.417	30	77.3%	-15.27 [-18.27, -12.27]		
Dulskas 2015	90	36.72	30	99.36	27.6	30	2.6%	-9.36 [-25.80, 7.08]		
Hasler-Gehrer	2019 65.2	55.93	56	74.1	52.51	59	1.8%	-8.90 [-28.75, 10.95]		
Hayashi 2019	55.1	27.01	23	69.7	27.65	23	2.8%	-14.60 [-30.40, 1.20]		
Parnasa 2021 Subtotal (95%	51.3 CI)	16.89	30 207	69.8	19.74	28 209	7.7%	-18.50 [-27.99, -9.01] -15.11 [-17.75, -12.47]		•
Heterogeneity:	Tau ² = 0.00; Chi ²	= 1.45	df = 5 (f	P = 0.92): I ² = 0%					
Test for overall	effect: Z = 11.21 (P < 0.00	0001)	0.01	,,, = 0,0					
3.8.2 Decafe										
Dulskas_deca Subtotal (95%	fe 2015 72 CI)	36	30 30	99.36	27.6	30 30	100.0% 100.0%	-27.36 [-43.59, -11.13] -27.36 [-43.59, -11.13]		-
Heterogeneity:	Not applicable									
Test for overall	effect: Z = 3.30 (F	= 0.001	0)							
									-100	-50 0 50 100
									-100	Favours [coffee] Favours [control]
Test for subgro	oup differences: C	hi ² = 2.1	3, df =	1 (P = 0	.14), 2 =	53.1%				- dreate [center] - dreate [centrel]
B Cesarean section										
D . Cesarean section		Coffee			Control			Mean Difference		Mean Difference
Study or Subara	oup Mean	SD	Total	Mear	I SI) Tota	al Weigh	IV. Random, 95% Cl		IV. Random, 95% CI
3.9.1 Caffeine	ap noun	00	retur	mean			in tronge	it injitaliaelinjeen ei		
Rahienoor 2018	37.22	16 31	50	36.83	163	5 5	0 47 39	0.40 6 800 8 800		+
Bozkurt Koseog	lu 2020 20.7	11.5	51	29.1	14.3	3 5	2 52.79	6 -8.40 [-13.41, -3.39]		T
Subtotal (95% C			101			10	2 100.01	[%] -4.24 [-12.00, 4.30]		T
Heterogeneity: 1 Test for overall e	auf = 30.12; Chif effect: Z = 0.96 (P =	= 4.50, = 0.34)	at=1 (F	P = 0.03);	20				
3.9.2 Decafe										
Göymen_decafe	2016 12.93	1.9	25	14.305	5 2.457	3 5	0 92.89	6 -1.38 [-2.38, -0.37]		
Kanza Gül_deca Subtotal (95% C	afe 2021 34	9.5	40 65	35	6.75	5 4 9	0 7.29	6 -1.00 [-4.61, 2.61] 6 -1.35 [-2.32, -0.38]		Ť
Heterogeneity: T Test for overall e	au ² = 0.00; Chi ² =	0.04, dt	f=1 (P	= 0.84);	I ² = 0%					
	silect. Z = 2.72 (F -	- 0.007)								
	sneut. 2 – 2.72 (r -	- 0.007)							-100	-50 0 50 100

Figure A12. Forest plot of time to first defecation by coffee types (caffeinated or decaffeinated coffee) in (**A**) colorectal surgery and (**B**) cesarean section.

Cesarean section

	Coffee			Control			Mean Difference			Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	104	IV, Random,	, 95% CI	
3.10.1 Caffeine												
Müller 2012	49.2	21.3	40	55.8	30	39	25.3%	-6.60 [-18.10, 4.90]				
Dulskas 2015	62.4	21.3	30	67.2	30	30	23.3%	-4.80 [-17.97, 8.37]				
Güngördük 2017	84	28.8	58	115.2	38.4	56	24.1%	-31.20 [-43.69, -18.71]				
Parnasa 2021	93.6	18.59	30	109.6	19.44	28	27.3%	-16.00 [-25.80, -6.20]				
Subtotal (95% CI)			158			153	100.0%	-14.68 [-25.76, -3.59]		•		
Heterogeneity: Tau ² = 92.05; Chi ² = 10.85, df = 3 (P = 0.01); l ² = 72%												
Test for overall effect: Z	= 2.60 (P	= 0.00	9)									
3.10.2 Decafe										_		
Dulskas_decafe 2015	44.4	21.3	30	67.2	30	30	100.0%	-22.80 [-35.97, -9.63]				
Subtotal (95% CI)			30			30	100.0%	-22.80 [-35.97, -9.63]		•		
Heterogeneity: Not appl	icable											
Test for overall effect: Z	= 3.39 (P	= 0.00	07)									
									-100	-50 0	50	100
									100	Favours [coffee] F	avours [control]	.00

Test for subgroup differences: $Chi^2 = 0.86$, df = 1 (P = 0.35), $l^2 = 0\%$

Figure A13. Forest plot of time to toleration of solid food by coffee types (caffeinated or decaffeinated coffee) in cesarean section.



Figure A14. Forest plot of length of hospital stay excluding studies using imputed statistics.

	Coffee			C	Control			Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI		
4.4.1 Colorectal surgery											
Müller 2012	40.6	16.1	40	46.4	20.1	39	7.3%	-5.80 [-13.84, 2.24]			
Hasler-Gehrer 2019	40	5.75	56	31	5.25	59	9.7%	9.00 [6.98, 11.02]	*		
Hayashi 2019	9.3	9.4	23	12.6	12.5	23	8.1%	-3.30 [-9.69, 3.09]			
Parnasa 2021	51.3	10.11	30	57.3	8.93	28	8.7%	-6.00 [-10.90, -1.10]			
Subtotal (95% CI)			149			149	33.7%	-1.23 [-10.75, 8.29]	+		
Heterogeneity: Tau ^x = 86.00; Chi ^x = 47.59, df = 3 (P < 0.00001); I ^z = 94%											
Test for overall effect: $Z = 0.25$ (P = 0.80)											
4.4.2 Cesarean section											
Göymen 2016	7	1.46	25	15.21	5.58	50	9.8%	-8.21 [-9.86, -6.56]	*		
Rabiepoor 2018	17.28	4.44	50	22.54	5.09	50	9.7%	-5.26 [-7.13, -3.39]	*		
Mohamed 2018	17.6	8.5	97	28.5	10.7	98	9.5%	-10.90 [-13.61, -8.19]	*		
Bozkurt Koseoglu 2020	8.6	3.3	51	11.3	7.5	52	9.7%	-2.70 [-4.93, -0.47]	*		
Kanza Gül 2021	39	14.75	40	33.2	8.375	40	8.6%	5.80 [0.54, 11.06]	.		
Subtotal (95% CI)			263			290	47.3%	-4.80 [-8.43, -1.17]	•		
Heterogeneity: Tau ² = 15.0	04; Chi²	= 47.70	, df = 4	(P < 0.0)0001);	l ² = 929	Хо				
Test for overall effect: Z = 3	2.59 (P =	= 0.010))								
4.4.2 Cumocological ours											
4.4.3 Gynecological surg	ery		50			50	~				
Gungorduk 2017	29.7	4.9	58	41.6	10.9	56	9.4%	-11.90 [-15.02, -8.78]	-		
Gungorduk 2020	19	5.5	49	25	6.75	47	9.6%	-6.00 [-8.47, -3.53]			
Subtotal (95% CI)			107			103	19.0%	-8.87 [-14.65, -3.09]	•		
Heterogeneity: Tau ² = 15.34; Chi ² = 8.44, df = 1 (P = 0.004); l ² = 88%											
Test for overall effect: $Z = 1$	3.01 (P =	= 0.003))								
Total (95% CI)			519			542	100.0%	-4.15 [-8.33, 0.03]	•		
Heterogeneity Tau ² = 45.76; Chi ² = 253.97; df = 10.(P < 0.00001); l ² = 96%											
Test for overall effect: 7 = 1	-100 -50 0 50 100										
Test for subgroup differences ($1 = 0.00$) Test for subgroup differences ($1 = 2.2$ df = 2.(P = 0.33) P = 10.0%									Favours [coffee] Favours [control]		
rest for subgroup differences; Chine 2.22, df = 2 (P = 0.33), if = 10.0%											









Figure A17. The funnel plot.

References

- Wolff, B.G.; Viscusi, E.R.; Delaney, C.P.; Du, W.; Techner, L. Patterns of gastrointestinal recovery after bowel resection and total abdominal hysterectomy: Pooled results from the placebo arms of alvimopan phase III North American clinical trials. *J. Am. Coll. Surg.* 2007, 205, 43–51. [CrossRef] [PubMed]
- Scarborough, J.E.; Schumacher, J.; Kent, K.C.; Heise, C.P.; Greenberg, C.C. Associations of specific postoperative complications with outcomes after elective colon resection: A procedure-targeted approach toward surgical quality improvement. *JAMA Surg.* 2017, 152, e164681. [CrossRef]
- 3. Gero, D.; Gié, O.; Hübner, M.; Demartines, N.; Hahnloser, D. Postoperative ileus: In search of an international consensus on definition, diagnosis, and treatment. *Langenbecks Arch. Surg.* **2017**, *402*, 149–158. [CrossRef] [PubMed]
- 4. Iyer, S.; Saunders, W.B.; Stemkowski, S. Economic burden of postoperative ileus associated with colectomy in the United States. *J. Manag. Care Pharm.* **2009**, *15*, 485–494. [CrossRef] [PubMed]
- Asgeirsson, T.; El-Badawi, K.I.; Mahmood, A.; Barletta, J.; Luchtefeld, M.; Senagore, A.J. Postoperative ileus: It costs more than you expect. J. Am. Coll. Surg. 2010, 210, 228–231. [CrossRef] [PubMed]
- Peters, E.G.; Pattamatta, M.; Smeets, B.J.J.; Brinkman, D.J.; Evers, S.M.A.A.; de Jonge, W.J.; Hiligsmann, M.; Luyer, M.D.P. The clinical and economical impact of postoperative ileus in patients undergoing colorectal surgery. *Neurogastroenterol. Motil.* 2020, 32, e13862. [CrossRef]
- 7. Abalo, R. Coffee and caffeine consumption for human health. Nutrients 2021, 13, 2918. [CrossRef] [PubMed]
- 8. Mattioli, A.V. Effects of caffeine and coffee consumption on cardiovascular disease and risk factors. *Future Cardiol.* 2007, *3*, 203–212. [CrossRef] [PubMed]
- Joós, G.; Jákim, J.; Kiss, B.; Szamosi, R.; Papp, T.; Felszeghy, S.; Sághy, T.; Nagy, G.; Szondy, Z. Involvement of adenosine A3 receptors in the chemotactic navigation of macrophages towards apoptotic cells. *Immunol. Lett.* 2017, 183, 62–72. [CrossRef] [PubMed]
- Gustafsson, U.O.; Scott, M.J.; Hubner, M.; Nygren, J.; Demartines, N.; Francis, N.; Rockall, T.A.; Young-Fadok, T.M.; Hill, A.G.; Soop, M.; et al. Guidelines for perioperative care in elective colorectal surgery: Enhanced Recovery After Surgery (ERAS[®]) Society Recommendations: 2018. World J. Surg. 2019, 43, 659–695. [CrossRef]
- Nelson, G.; Bakkum-Gamez, J.; Kalogera, E.; Glaser, G.; Altman, A.; Meyer, L.A.; Taylor, J.S.; Iniesta, M.; Lasala, J.; Mena, G.; et al. Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations— 2019 update. *Int. J. Gynecol. Cancer* 2019, 29, 651–668. [CrossRef] [PubMed]
- 12. Eamudomkarn, N.; Kietpeerakool, C.; Kaewrudee, S.; Jampathong, N.; Ngamjarus, C.; Lumbiganon, P. Effect of postoperative coffee consumption on gastrointestinal function after abdominal surgery: A systematic review and meta-analysis of randomized controlled trials. *Sci. Rep.* **2018**, *8*, 17349. [CrossRef] [PubMed]
- 13. Gkegkes, I.D.; Minis, E.E.; Iavazzo, C. Effect of caffeine intake on postoperative ileus: A systematic review and meta-analysis. *Dig. Surg.* **2020**, *37*, 22–31. [CrossRef] [PubMed]
- 14. Cornwall, H.L.; Edwards, B.A.; Curran, J.F.; Boyce, S. Coffee to go? The effect of coffee on resolution of ileus following abdominal surgery: A systematic review and meta-analysis of randomised controlled trials. *Clin. Nutr.* **2020**, *39*, 1385–1394. [CrossRef]
- 15. Kane, T.D.; Tubog, T.D.; Schmidt, J.R. The use of coffee to decrease the incidence of postoperative ileus: A systematic review and meta-analysis. *J. Perianesth. Nurs.* 2020, 35, 171–177.e1. [CrossRef]
- Shamseer, L.; Moher, D.; Clarke, M.; Ghersi, D.; Liberati, A.; Petticrew, M.; Shekelle, P.; Stewart, L.A.; PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation. *BMJ* 2015, 350, g7647. [CrossRef]
- 17. Sterne, J.A.C.; Savović, J.; Page, M.J.; Elbers, R.G.; Blencowe, N.S.; Boutron, I.; Cates, C.J.; Cheng, H.Y.; Corbett, M.S.; Eldridge, S.M.; et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. *BMJ* **2019**, *366*, 14898. [CrossRef] [PubMed]
- Guyatt, G.; Oxman, A.D.; Akl, E.A.; Kunz, R.; Vist, G.; Brozek, J.; Norris, S.; Falck-Ytter, Y.; Glasziou, P.; DeBeer, H.; et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *J. Clin. Epidemiol.* 2011, 64, 383–394. [CrossRef]
- 19. Higgins, J.P.T.; Thomas, J. Cochrane Handbook for Systematic Reviews of Interventions Version 6.2. 2021. Available online: https://training.cochrane.org/handbook/current (accessed on 29 September 2021).
- 20. Furukawa, T.A.; Barbui, C.; Cipriani, A.; Brambilla, P.; Watanabe, N. Imputing missing standard deviations in meta-analyses can provide accurate results. *J. Clin. Epidemiol.* 2006, *59*, 7–10. [CrossRef]
- Müller, S.A.; Rahbari, N.N.; Schneider, F.; Warschkow, R.; Simon, T.; von Frankenberg, M.; Bork, U.; Weitz, J.; Schmied, B.M.; Büchler, M.W. Randomized clinical trial on the effect of coffee on postoperative ileus following elective colectomy. *Br. J. Surg.* 2012, 99, 1530–1538. [CrossRef]
- Dulskas, A.; Klimovskij, M.; Vitkauskiene, M.; Samalavicius, N.E. Effect of coffee on the length of postoperative ileus after elective laparoscopic left-sided colectomy: A randomized, prospective single-center study. *Dis. Colon Rectum.* 2015, 58, 1064–1069. [CrossRef]
- 23. Piric, M.; Pasic, F.; Rifatbegovic, Z.; Konjic, F. The Effects of Drinking Coffee While Recovering from Colon and Rectal Resection Surgery. *Med. Arch.* 2015, 69, 357–361. [CrossRef] [PubMed]
- 24. Goymen, A.; Simsek, Y.; Ozkaplan, S.E.; Ozdurak, H.I.; Akpak, Y.K.; Semiz, A.; Oral, S. Effect of gum chewing and coffee consumption on intestinal motility in caesarean sections. *J. Clin. Anal. Med.* **2017**, *8*, 411e5. [CrossRef]

- Güngördük, K.; Özdemir, İ.A.; Güngördük, Ö.; Gülseren, V.; Gokçü, M.; Sancı, M. Effects of coffee consumption on gut recovery after surgery of gynecological cancer patients: A randomized controlled trial. *Am. J. Obstet Gynecol.* 2017, 216, 145.e1–145.e7. [CrossRef] [PubMed]
- Mohamed, S. Immediate Postoperative Coffee Consumption Stimulates Early Gut Recovery after Cesarean Section. 2018. Available online: https://www.semanticscholar.org/paper/Immediate-Postoperative-Coffee-Consumption-Early-Sherbeny/ 8b790eb67f979bea8affae03fe5010167ae166c0?p2df (accessed on 1 October 2021).
- 27. Rabiepoor, S.; Yas, A.; Navaei, J.; Khalkhali, H.R. Does coffee affect the bowel function after caesarean section? *Eur. J. Obstet. Gynecol. Reprod. Biol.* **2018**, 220, 96–99. [CrossRef]
- 28. Hasler-Gehrer, S.; Linecker, M.; Keerl, A.; Slieker, J.; Descloux, A.; Rosenberg, R.; Seifert, B.; Nocito, A. Does coffee intake reduce postoperative ileus after laparoscopic elective colorectal surgery? A prospective, randomized controlled study: The coffee study. *Dis. Colon Rectum* **2019**, *62*, 997–1004. [CrossRef] [PubMed]
- 29. Hayashi, K.; Tsunoda, A.; Shiraishi, A.; Kusanagi, H. Quantification of the effects of coffee on postoperative ileus after laparoscopic ventral rectopexy: A randomized controlled trial. *Eur. Surg.* **2019**, *51*, 325–332. [CrossRef]
- 30. Bozkurt Koseoglu, S.; Korkmaz Toker, M.; Gokbel, I.; Celikkol, O.; Gungorduk, K. Can coffee consumption be used to accelerate the recovery of bowel function after cesarean section? Randomized prospective trial. *Ginekol. Pol.* **2020**, *91*, 85–90. [CrossRef]
- Gungorduk, K.; Paskal, E.K.; Demirayak, G.; Köseoğlu, S.B.; Akbaba, E.; Ozdemir, I.A. Coffee consumption for recovery of intestinal function after laparoscopic gynecological surgery: A randomized controlled trial. *Int. J. Surg.* 2020, *82*, 130–135. [CrossRef] [PubMed]
- 32. Kanza Gül, D.; Şolt Kırca, A. Effects of acupressure, gum chewing and coffee consumption on the gastrointestinal system after caesarean section under spinal anaesthesia. *J. Obstet Gynaecol.* **2021**, *41*, 573–580. [CrossRef]
- Parnasa, S.Y.; Marom, G.; Bdolah-Abram, T.; Gefen, R.; Luques, L.; Michael, S.; Mizrahi, I.; Abu-Gazala, M.; Rivkind, A.I.; Mintz, Y.; et al. Does caffeine enhance bowel recovery after elective colorectal resection? A prospective double-blinded randomized clinical trial. *Tech. Coloproctol.* 2021, 25, 831–839. [CrossRef] [PubMed]
- Lohsiriwat, V.; Jitmungngan, R.; Chadbunchachai, W.; Ungprasert, P. Enhanced recovery after surgery in emergency resection for obstructive colorectal cancer: A systematic review and meta-analysis. *Int. J. Colorectal. Dis.* 2020, 35, 1453–1461. [CrossRef] [PubMed]
- McKechnie, T.; Anpalagan, T.; Ichhpuniani, S.; Lee, Y.; Ramji, K.; Eskicioglu, C. Selective opioid antagonists following bowel resection for prevention of postoperative ileus: A systematic review and meta-analysis. *J. Gastrointest. Surg.* 2021, 25, 1601–1624. [CrossRef] [PubMed]
- Mattioli, A.V.; Migaldi, M.; Farinetti, A. Coffee in hypertensive women with asymptomatic peripheral arterial disease: A potential nutraceutical effect. J. Cardiovasc. Med. 2018, 19, 183–185. [CrossRef] [PubMed]
- Echeverri, D.; Montes, F.R.; Cabrera, M.; Galán, A.; Prieto, A. Caffeine's Vascular Mechanisms of Action. Int. J. Vasc. Med. 2010, 2010, 834060. [CrossRef] [PubMed]
- Mattioli, A.V.; Nasi, M.; Farinetti, A.; Gelmini, R. Effects of caffeine on colon: A potential clinical use of coffee in surgical patients. *Dig. Surg.* 2020, *37*, 265–266. [CrossRef] [PubMed]
- Cui, W.Q.; Wang, S.T.; Pan, D.; Chang, B.; Sang, L.X. Caffeine and its main targets of colorectal cancer. World J. Gastrointest. Oncol. 2020, 12, 149–172. [CrossRef] [PubMed]
- Liu, D.; Jing, X.; Cao, S.; Liu, X.; Tan, X.; Jiang, H.; Niu, Z.; Su, M.; Zhang, J.; Zhang, X.; et al. Impact of drinking Chinese green tea on postoperative short outcomes for gastric cancer: A randomized controlled trial. *Eur. J. Clin. Nutr.* 2021, 75, 1568–1577. [CrossRef] [PubMed]
- 41. Tajik, N.; Tajik, M.; Mack, I.; Enck, P. The potential effects of chlorogenic acid, the main phenolic components in coffee, on health: A comprehensive review of the literature. *Eur. J. Nutr.* **2017**, *56*, 2215–2244. [CrossRef]
- 42. Dos Santos, M.D.; Almeida, M.C.; Lopes, N.P.; de Souza, G.E. Evaluation of the anti-inflammatory, analgesic and antipyretic activities of the natural polyphenol chlorogenic acid. *Biol. Pharm. Bull.* 2006, 29, 2236–2240. [CrossRef]
- Krakauer, T. The polyphenol chlorogenic acid inhibits staphylococcal exotoxin-induced inflammatory cytokines and chemokines. *Immunopharmacol. Immunotoxicol.* 2002, 24, 113–119. [CrossRef] [PubMed]
- Li, Q.; Liu, Y.; Sun, X.; Yin, Z.; Li, H.; Cheng, C.; Liu, L.; Zhang, R.; Liu, F.; Zhou, Q.; et al. Caffeinated and decaffeinated coffee consumption and risk of all-cause mortality: A dose-response meta-analysis of cohort studies. *J. Hum. Nutr. Diet.* 2019, 32, 279–287. [CrossRef] [PubMed]
- Kennedy, O.J.; Roderick, P.; Buchanan, R.; Fallowfield, J.A.; Hayes, P.C.; Parkes, J. Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: A systematic review and dose-response meta-analysis. *BMJ Open* 2017, 7, e013739. [CrossRef] [PubMed]
- Casiglia, E.; Bongiovì, S.; Paleari, C.D.; Petucco, S.; Boni, M.; Colangeli, G.; Penzo, M.; Pessina, A.C. Haemodynamic effects of coffee and caffeine in normal volunteers: A placebo-controlled clinical study. *J. Intern. Med.* 1991, 229, 501–504. [CrossRef] [PubMed]
- 47. Ribeiro, E.M.; Alves, M.; Costa, J.; Ferreira, J.J.; Pinto, F.J.; Caldeira, D. Safety of coffee consumption after myocardial infarction: A systematic review and meta-analysis. *Nutr. Metab. Cardiovasc. Dis.* **2020**, *30*, 2146–2158. [CrossRef] [PubMed]
- 48. Kelly, A.J.; Alfirevic, Z.; Ghosh, A. Outpatient versus inpatient induction of labour for improving birth outcomes. *Cochrane Database Syst. Rev.* 2013, *11*, CD007372. [CrossRef] [PubMed]

- 49. Pereira Gomes Morais, E.; Riera, R.; Porfírio, G.J.; Macedo, C.R.; Sarmento Vasconcelos, V.; de Souza Pedrosa, A.; Torloni, M.R. Chewing gum for enhancing early recovery of bowel function after caesarean section. *Cochrane Database Syst. Rev.* **2016**, *10*, CD011562. [CrossRef]
- 50. Hamel, J.F.; Sabbagh, C.; Alves, A.; Regimbeau, J.M.; Vignaud, T.; Venara, A. Comparison of treatment to improve gastrointestinal functions after colorectal surgery within enhanced recovery programmes: A systematic review and meta-analysis. *Sci. Rep.* **2021**, *11*, 7423. [CrossRef]